A molecular understanding of alphavirus entry and antibody protection.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
accepted:
01
11
2022
medline:
18
5
2023
pubmed:
7
12
2022
entrez:
6
12
2022
Statut:
ppublish
Résumé
Alphaviruses are arthropod-transmitted RNA viruses that cause epidemics of human infection and disease on a global scale. These viruses are classified as either arthritogenic or encephalitic based on their genetic relatedness and the clinical syndromes they cause. Although there are currently no approved therapeutics or vaccines against alphaviruses, passive transfer of monoclonal antibodies confers protection in animal models. This Review highlights recent advances in our understanding of the host factors required for alphavirus entry, the mechanisms of action by which protective antibodies inhibit different steps in the alphavirus infection cycle and candidate alphavirus vaccines currently under clinical evaluation that focus on humoral immunity. A comprehensive understanding of alphavirus entry and antibody-mediated protection may inform the development of new classes of countermeasures for these emerging viruses.
Identifiants
pubmed: 36474012
doi: 10.1038/s41579-022-00825-7
pii: 10.1038/s41579-022-00825-7
pmc: PMC9734810
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-407Subventions
Organisme : NIAID NIH HHS
ID : R01 AI143673
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI164653
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142790
Pays : United States
Informations de copyright
© 2022. Springer Nature Limited.
Références
Suhrbier, A., Jaffar-Bandjee, M. C. & Gasque, P. Arthritogenic alphaviruses — an overview. Nat. Rev. Rheumatol. 8, 420–429 (2012).
doi: 10.1038/nrrheum.2012.64
pubmed: 22565316
Carrera, J. P. et al. Eastern equine encephalitis in Latin America. N. Engl. J. Med. 369, 732–744 (2013).
doi: 10.1056/NEJMoa1212628
pubmed: 23964935
Morens, D. M., Folkers, G. K. & Fauci, A. S. Eastern equine encephalitis virus — another emergent arbovirus in the United States. N. Engl. J. Med. 381, 1989–1992 (2019).
doi: 10.1056/NEJMp1914328
pubmed: 31747726
Baker, R. E. et al. Infectious disease in an era of global change. Nat. Rev. Microbiol. 20, 193–205 (2022).
doi: 10.1038/s41579-021-00639-z
pubmed: 34646006
Weaver, S. C. & Reisen, W. K. Present and future arboviral threats. Antivir. Res. 85, 328–345 (2010).
doi: 10.1016/j.antiviral.2009.10.008
pubmed: 19857523
Schuffenecker, I. et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3, e263 (2006).
pmcid: 1463904
doi: 10.1371/journal.pmed.0030263
pubmed: 16700631
Rezza, G. Dengue and chikungunya: long-distance spread and outbreaks in naive areas. Pathog. Glob. Health 108, 349–355 (2014).
pmcid: 4394667
doi: 10.1179/2047773214Y.0000000163
pubmed: 25491436
Harley, D., Sleigh, A. & Ritchie, S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin. Microbiol. Rev. 14, 909–932 (2001).
pmcid: 89008
doi: 10.1128/CMR.14.4.909-932.2001
pubmed: 11585790
Aguilar-Luis, M. A. et al. An emerging public health threat: Mayaro virus increases its distribution in Peru. Int. J. Infect. Dis. 92, 253–258 (2020).
doi: 10.1016/j.ijid.2020.01.024
pubmed: 31978575
Sidwell, R. W. & Smee, D. F. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antivir. Res. 57, 101–111 (2003).
doi: 10.1016/S0166-3542(02)00203-6
pubmed: 12615306
Weaver, S. C. et al. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 348, 436–440 (1996).
doi: 10.1016/S0140-6736(96)02275-1
pubmed: 8709783
Torres-Ruesta, A., Chee, R. S. & Ng, L. F. P. Insights into antibody-mediated alphavirus immunity and vaccine development landscape. Microorganisms https://doi.org/10.3390/microorganisms9050899 (2021).
doi: 10.3390/microorganisms9050899
pmcid: 8145166
pubmed: 33922370
Kafai, N. M., Diamond, M. S. & Fox, J. M. Distinct cellular tropism and immune responses to alphavirus infection. Annu. Rev. Immunol. 40, 615–649 (2022).
doi: 10.1146/annurev-immunol-101220-014952
pubmed: 35134315
Holmes, A. C., Basore, K., Fremont, D. H. & Diamond, M. S. A molecular understanding of alphavirus entry. PLoS Pathog. 16, e1008876 (2020).
pmcid: 7580943
doi: 10.1371/journal.ppat.1008876
pubmed: 33091085
Voss, J. E. et al. Glycoprotein organization of chikungunya virus particles revealed by X-ray crystallography. Nature 468, 709–712 (2010).
doi: 10.1038/nature09555
pubmed: 21124458
Li, L., Jose, J., Xiang, Y., Kuhn, R. J. & Rossmann, M. G. Structural changes of envelope proteins during alphavirus fusion. Nature 468, 705–708 (2010).
pmcid: 3057476
doi: 10.1038/nature09546
pubmed: 21124457
Snyder, J. E. et al. Functional characterization of the alphavirus TF protein. J. Virol. 87, 8511–8523 (2013).
pmcid: 3719798
doi: 10.1128/JVI.00449-13
pubmed: 23720714
Jose, J., Snyder, J. E. & Kuhn, R. J. A structural and functional perspective of alphavirus replication and assembly. Fut. Microbiol. 4, 837–856 (2009).
doi: 10.2217/fmb.09.59
Hasan, S. S. et al. Cryo-EM structures of Eastern equine encephalitis virus reveal mechanisms of virus disassembly and antibody neutralization. Cell Rep. 25, 3136–3147.e5 (2018).
pmcid: 6302666
doi: 10.1016/j.celrep.2018.11.067
pubmed: 30540945
Basore, K. et al. Cryo-EM structure of chikungunya virus in complex with the Mxra8 receptor. Cell 177, 1725–1737.e16 (2019).
pmcid: 7227486
doi: 10.1016/j.cell.2019.04.006
pubmed: 31080061
Zhang, X., Fugere, M., Day, R. & Kielian, M. Furin processing and proteolytic activation of Semliki Forest virus. J. Virol. 77, 2981–2989 (2003).
pmcid: 149766
doi: 10.1128/JVI.77.5.2981-2989.2003
pubmed: 12584323
de Curtis, I. & Simons, K. Dissection of Semliki Forest virus glycoprotein delivery from the trans-Golgi network to the cell surface in permeabilized BHK cells. Proc. Natl Acad. Sci. USA 85, 8052–8056 (1988).
pmcid: 282352
doi: 10.1073/pnas.85.21.8052
pubmed: 3186706
Uchime, O., Fields, W. & Kielian, M. The role of E3 in pH protection during alphavirus assembly and exit. J. Virol. 87, 10255–10262 (2013).
pmcid: 3754015
doi: 10.1128/JVI.01507-13
pubmed: 23864626
Sjöberg, M., Lindqvist, B. & Garoff, H. Activation of the alphavirus spike protein is suppressed by bound E3. J. Virol. 85, 5644–5650 (2011).
pmcid: 3094962
doi: 10.1128/JVI.00130-11
pubmed: 21430054
Snyder, A. J. & Mukhopadhyay, S. The alphavirus E3 glycoprotein functions in a clade-specific manner. J. Virol. 86, 13609–13620 (2012).
pmcid: 3503070
doi: 10.1128/JVI.01805-12
pubmed: 23035234
Chen, L. et al. Implication for alphavirus host-cell entry and assembly indicated by a 3.5A resolution cryo-EM structure. Nat. Commun. 9, 5326 (2018).
pmcid: 6294011
doi: 10.1038/s41467-018-07704-x
pubmed: 30552337
Davis, N. L., Pence, D. F., Meyer, W. J., Schmaljohn, A. L. & Johnston, R. E. Alternative forms of a strain-specific neutralizing antigenic site on the Sindbis virus E2 glycoprotein. Virology 161, 101–108 (1987).
doi: 10.1016/0042-6822(87)90175-9
pubmed: 2445100
Flynn, D. C., Olmsted, R. A., Mackenzie, J. M. Jr & Johnston, R. E. Antibody-mediated activation of Sindbis virus. Virology 166, 82–90 (1988).
doi: 10.1016/0042-6822(88)90149-3
pubmed: 3413988
Meyer, W. J. & Johnston, R. E. Structural rearrangement of infecting Sindbis virions at the cell surface: mapping of newly accessible epitopes. J. Virol. 67, 5117–5125 (1993).
pmcid: 237909
doi: 10.1128/jvi.67.9.5117-5125.1993
pubmed: 7688818
Smith, T. J. et al. Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc. Natl Acad. Sci. USA 92, 10648–10652 (1995).
pmcid: 40669
doi: 10.1073/pnas.92.23.10648
pubmed: 7479858
Mukhopadhyay, S. et al. Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses. Structure 14, 63–73 (2006).
pmcid: 2757649
doi: 10.1016/j.str.2005.07.025
pubmed: 16407066
Ubol, S. & Griffin, D. E. Identification of a putative alphavirus receptor on mouse neural cells. J. Virol. 65, 6913–6921 (1991).
pmcid: 250794
doi: 10.1128/jvi.65.12.6913-6921.1991
pubmed: 1658382
Vrati, S., Kerr, P. J., Weir, R. C. & Dalgarno, L. Entry kinetics and mouse virulence of Ross River virus mutants altered in neutralization epitopes. J. Virol. 70, 1745–1750 (1996).
pmcid: 189999
doi: 10.1128/jvi.70.3.1745-1750.1996
pubmed: 8627696
Song, H. et al. Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to chikungunya virus envelope protein. Cell 177, 1714–1724.e12 (2019).
doi: 10.1016/j.cell.2019.04.008
pubmed: 31080063
Zhang, R. et al. Mxra8 is a receptor for multiple arthritogenic alphaviruses. Nature 557, 570–574 (2018).
pmcid: 5970976
doi: 10.1038/s41586-018-0121-3
pubmed: 29769725
Ramsey, J. & Mukhopadhyay, S. Disentangling the frames, the state of research on the alphavirus 6K and TF proteins. Viruses https://doi.org/10.3390/v9080228 (2017).
doi: 10.3390/v9080228
pmcid: 5580485
pubmed: 28820485
Loewy, A., Smyth, J., von Bonsdorff, C. H., Liljestrom, P. & Schlesinger, M. J. The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process. J. Virol. 69, 469–475 (1995).
pmcid: 188595
doi: 10.1128/jvi.69.1.469-475.1995
pubmed: 7983743
Lescar, J. et al. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105, 137–148 (2001).
doi: 10.1016/S0092-8674(01)00303-8
pubmed: 11301009
Roussel, A. et al. Structure and interactions at the viral surface of the envelope protein E1 of Semliki Forest virus. Structure 14, 75–86 (2006).
doi: 10.1016/j.str.2005.09.014
pubmed: 16407067
Gibbons, D. L. et al. Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography. Cell 114, 573–583 (2003).
doi: 10.1016/S0092-8674(03)00683-4
pubmed: 13678581
Gibbons, D. L. et al. Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature 427, 320–325 (2004).
doi: 10.1038/nature02239
pubmed: 14737160
Jin, J. et al. Neutralizing antibodies inhibit chikungunya virus budding at the plasma membrane. Cell Host Microbe 24, 417–428.e5 (2018).
pmcid: 6137268
doi: 10.1016/j.chom.2018.07.018
pubmed: 30146390
Soonsawad, P. et al. Structural evidence of glycoprotein assembly in cellular membrane compartments prior to alphavirus budding. J. Virol. 84, 11145–11151 (2010).
pmcid: 2953181
doi: 10.1128/JVI.00036-10
pubmed: 20739526
Jose, J., Taylor, A. B. & Kuhn, R. J. Spatial and temporal analysis of alphavirus replication and assembly in mammalian and mosquito cells. mBio https://doi.org/10.1128/mBio.02294-16 (2017).
doi: 10.1128/mBio.02294-16
pmcid: 5312085
pubmed: 28196962
Silva, L. A. et al. A single-amino-acid polymorphism in chikungunya virus e2 glycoprotein influences glycosaminoglycan utilization. J. Virol. 88, 2385–2397 (2014).
pmcid: 3958064
doi: 10.1128/JVI.03116-13
pubmed: 24371059
Tanaka, A. et al. Genome-wide screening uncovers the significance of N-sulfation of heparan sulfate as a host cell factor for chikungunya virus infection. J. Virol. https://doi.org/10.1128/jvi.00432-17 (2017).
doi: 10.1128/jvi.00432-17
pmcid: 5625519
pubmed: 28768868
Zhang, W., Heil, M., Kuhn, R. J. & Baker, T. S. Heparin binding sites on Ross River virus revealed by electron cryo-microscopy. Virology 332, 511–518 (2005).
doi: 10.1016/j.virol.2004.11.043
pubmed: 15680416
Byrnes, A. P. & Griffin, D. E. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72, 7349–7356 (1998).
pmcid: 109959
doi: 10.1128/JVI.72.9.7349-7356.1998
pubmed: 9696831
Gardner, C. L., Ebel, G. D., Ryman, K. D. & Klimstra, W. B. Heparan sulfate binding by natural Eastern equine encephalitis viruses promotes neurovirulence. Proc. Natl Acad. Sci. USA 108, 16026–16031 (2011).
pmcid: 3179095
doi: 10.1073/pnas.1110617108
pubmed: 21896745
Gardner, C. L. et al. Natural variation in the heparan sulfate binding domain of the Eastern equine encephalitis virus E2 glycoprotein alters interactions with cell surfaces and virulence in mice. J. Virol. 87, 8582–8590 (2013).
pmcid: 3719831
doi: 10.1128/JVI.00937-13
pubmed: 23720725
Bernard, K. A., Klimstra, W. B. & Johnston, R. E. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276, 93–103 (2000).
doi: 10.1006/viro.2000.0546
pubmed: 11021998
Klimstra, W. B., Ryman, K. D. & Johnston, R. E. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 72, 7357–7366 (1998).
pmcid: 109960
doi: 10.1128/JVI.72.9.7357-7366.1998
pubmed: 9696832
Ashbrook, A. W. et al. Residue 82 of the chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice. J. Virol. 88, 12180–12192 (2014).
pmcid: 4248890
doi: 10.1128/JVI.01672-14
pubmed: 25142598
Klimstra, W. B., Nangle, E. M., Smith, M. S., Yurochko, A. D. & Ryman, K. D. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol. 77, 12022–12032 (2003).
pmcid: 254289
doi: 10.1128/JVI.77.22.12022-12032.2003
pubmed: 14581539
Feinberg, H., Mitchell, D. A., Drickamer, K. & Weis, W. I. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294, 2163–2166 (2001).
doi: 10.1126/science.1066371
pubmed: 11739956
Jemielity, S. et al. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 9, e1003232 (2013).
pmcid: 3610696
doi: 10.1371/journal.ppat.1003232
pubmed: 23555248
Moller-Tank, S., Kondratowicz, A. S., Davey, R. A., Rennert, P. D. & Maury, W. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J. Virol. 87, 8327–8341 (2013).
pmcid: 3719829
doi: 10.1128/JVI.01025-13
pubmed: 23698310
Kirui, J. et al. The phosphatidylserine receptor TIM-1 enhances authentic chikungunya virus cell entry. Cells https://doi.org/10.3390/cells10071828 (2021).
doi: 10.3390/cells10071828
pmcid: 8303237
pubmed: 34359995
Wang, K. S., Kuhn, R. J., Strauss, E. G., Ou, S. & Strauss, J. H. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J. Virol. 66, 4992–5001 (1992).
pmcid: 241351
doi: 10.1128/jvi.66.8.4992-5001.1992
pubmed: 1385835
Ludwig, G. V., Kondig, J. P. & Smith, J. F. A putative receptor for Venezuelan equine encephalitis virus from mosquito cells. J. Virol. 70, 5592–5599 (1996).
pmcid: 190519
doi: 10.1128/jvi.70.8.5592-5599.1996
pubmed: 8764073
Wintachai, P. et al. Identification of prohibitin as a chikungunya virus receptor protein. J. Med. Virol. 84, 1757–1770 (2012).
doi: 10.1002/jmv.23403
pubmed: 22997079
De Caluwé, L. et al. The CD147 protein complex is involved in entry of chikungunya virus and related alphaviruses in human cells. Front. Microbiol. 12, 615165 (2021).
pmcid: 7946996
doi: 10.3389/fmicb.2021.615165
pubmed: 33717005
Helenius, A. et al. Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus. Proc. Natl Acad. Sci. USA 75, 3846–3850 (1978).
pmcid: 392884
doi: 10.1073/pnas.75.8.3846
pubmed: 278998
Rose, P. P. et al. Natural resistance-associated macrophage protein is a cellular receptor for Sindbis virus in both insect and mammalian hosts. Cell Host Microbe 10, 97–104 (2011).
pmcid: 3164510
doi: 10.1016/j.chom.2011.06.009
pubmed: 21843867
Kim, A. S. et al. An evolutionary insertion in the Mxra8 receptor-binding site confers resistance to alphavirus infection and pathogenesis. Cell Host Microbe 27, 428–440.e9 (2020).
pmcid: 7163869
doi: 10.1016/j.chom.2020.01.008
pubmed: 32075743
Zhang, R. et al. Expression of the Mxra8 receptor promotes alphavirus infection and pathogenesis in mice and Drosophila. Cell Rep. 28, 2647–2658.e5 (2019).
pmcid: 6745702
doi: 10.1016/j.celrep.2019.07.105
pubmed: 31484075
Ma, H. et al. LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. Nature 588, 308–314 (2020).
pmcid: 7769003
doi: 10.1038/s41586-020-2915-3
pubmed: 33208938
Basore, K. et al. Structure of Venezuelan equine encephalitis virus in complex with the LDLRAD3 receptor. Nature 598, 672–676 (2021).
pmcid: 8550936
doi: 10.1038/s41586-021-03963-9
pubmed: 34646020
Ma, B., Huang, C., Ma, J., Xiang, Y. & Zhang, X. Structure of Venezuelan equine encephalitis virus with its receptor LDLRAD3. Nature 598, 677–681 (2021).
doi: 10.1038/s41586-021-03909-1
pubmed: 34646021
Clark, L. E. et al. VLDLR and ApoER2 are receptors for multiple alphaviruses. Nature 602, 475–480 (2022).
doi: 10.1038/s41586-021-04326-0
pubmed: 34929721
Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19. N. Engl. J. Med. 386, 2188–2200 (2022).
doi: 10.1056/NEJMoa2116620
pubmed: 35443106
Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–1950 (2021).
doi: 10.1056/NEJMoa2107934
pubmed: 34706189
Robbie, G. J. et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother. 57, 6147–6153 (2013).
pmcid: 3837853
doi: 10.1128/AAC.01285-13
pubmed: 24080653
Boere, W. A., Benaissa-Trouw, B. J., Harmsen, M., Kraaijeveld, C. A. & Snippe, H. Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J. Gen. Virol. 64, 1405–1408 (1983).
doi: 10.1099/0022-1317-64-6-1405
pubmed: 6854274
Boere, W. A. et al. Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. J. Virol. 52, 575–582 (1984).
pmcid: 254560
doi: 10.1128/jvi.52.2.575-582.1984
pubmed: 6208379
Stanley, J., Cooper, S. J. & Griffin, D. E. Alphavirus neurovirulence: monoclonal antibodies discriminating wild-type from neuroadapted Sindbis virus. J. Virol. 56, 110–119 (1985).
pmcid: 252488
doi: 10.1128/jvi.56.1.110-119.1985
pubmed: 2411947
Stec, D. S., Waddell, A., Schmaljohn, C. S., Cole, G. A. & Schmaljohn, A. L. Antibody-selected variation and reversion in Sindbis virus neutralization epitopes. J. Virol. 57, 715–720 (1986).
pmcid: 252797
doi: 10.1128/jvi.57.3.715-720.1986
pubmed: 2419586
Vrati, S., Fernon, C. A., Dalgarno, L. & Weir, R. C. Location of a major antigenic site involved in Ross River virus neutralization. Virology 162, 346–353 (1988).
doi: 10.1016/0042-6822(88)90474-6
pubmed: 2448952
Roehrig, J. T., Day, J. W. & Kinney, R. M. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 118, 269–278 (1982).
doi: 10.1016/0042-6822(82)90346-4
pubmed: 6178209
Roehrig, J. T., Gorski, D. & Schlesinger, M. J. Properties of monoclonal antibodies directed against the glycoproteins of Sindbis virus. J. Gen. Virol. 59, 421–425 (1982).
doi: 10.1099/0022-1317-59-2-421
pubmed: 6281377
Roehrig, J. T. & Mathews, J. H. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 142, 347–356 (1985).
doi: 10.1016/0042-6822(85)90343-5
pubmed: 2414905
Mayne, J. T., Rice, C. M., Strauss, E. G., Hunkapiller, M. W. & Strauss, J. H. Biochemical studies of the maturation of the small Sindbis virus glycoprotein E3. Virology 134, 338–357 (1984).
doi: 10.1016/0042-6822(84)90302-7
pubmed: 6443592
Parker, M. D. et al. Antibody to the E3 glycoprotein protects mice against lethal Venezuelan equine encephalitis virus infection. J. Virol. 84, 12683–12690 (2010).
pmcid: 3004303
doi: 10.1128/JVI.01345-10
pubmed: 20926570
Warter, L. et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J. Immunol. 186, 3258–3264 (2011).
doi: 10.4049/jimmunol.1003139
pubmed: 21278338
Pal, P. et al. Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. PLoS Pathog. 9, e1003312 (2013).
pmcid: 3630103
doi: 10.1371/journal.ppat.1003312
pubmed: 23637602
Fox, J. M. et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163, 1095–1107 (2015).
pmcid: 4659373
doi: 10.1016/j.cell.2015.10.050
pubmed: 26553503
Smith, S. A. et al. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18, 86–95 (2015).
pmcid: 4501771
doi: 10.1016/j.chom.2015.06.009
pubmed: 26159721
Fong, R. H. et al. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J. Virol. 88, 14364–14379 (2014).
pmcid: 4249124
doi: 10.1128/JVI.01943-14
pubmed: 25275138
Quiroz, J. A. et al. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. PLoS Pathog. 15, e1008061 (2019).
pmcid: 6837291
doi: 10.1371/journal.ppat.1008061
pubmed: 31697791
Malonis, R. J. et al. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2100104118 (2021).
doi: 10.1073/pnas.2100104118
pmcid: 8449321
pubmed: 34507983
Goh, L. Y. et al. Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin. Immunol. 149, 487–497 (2013).
doi: 10.1016/j.clim.2013.10.004
pubmed: 24239837
Powell, L. A. et al. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease. PLoS Pathog. 16, e1008517 (2020).
pmcid: 7252634
doi: 10.1371/journal.ppat.1008517
pubmed: 32365139
Powell, L. A. et al. Human mAbs broadly protect against arthritogenic alphaviruses by recognizing conserved elements of the Mxra8 receptor-binding site. Cell Host Microbe 28, 699–711.e7 (2020).
pmcid: 7666055
doi: 10.1016/j.chom.2020.07.008
pubmed: 32783883
Earnest, J. T. et al. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. J. Exp. Med. 216, 2282–2301 (2019).
pmcid: 6781005
doi: 10.1084/jem.20190736
pubmed: 31337735
Kim, A. S. et al. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein. Nat. Microbiol. 4, 187–197 (2019).
doi: 10.1038/s41564-018-0286-4
pubmed: 30455470
Williamson, L. E. et al. Human antibodies protect against aerosolized Eastern equine encephalitis virus infection. Cell 183, 1884–1900.e23 (2020).
pmcid: 7806206
doi: 10.1016/j.cell.2020.11.011
pubmed: 33301709
Liu, J. L., Shriver-Lake, L. C., Zabetakis, D., Goldman, E. R. & Anderson, G. P. Selection of single-domain antibodies towards Western equine encephalitis virus. Antibodies https://doi.org/10.3390/antib7040044 (2018).
doi: 10.3390/antib7040044
pmcid: 6698954
pubmed: 31544894
Kafai, N. M. et al. Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge. J. Exp. Med. https://doi.org/10.1084/jem.20212532 (2022).
doi: 10.1084/jem.20212532
pmcid: 9195047
pubmed: 35297953
Porta, J. et al. Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. J. Virol. 88, 9616–9623 (2014).
pmcid: 4136364
doi: 10.1128/JVI.01286-14
pubmed: 24920796
Sun, S. et al. Structural analyses at pseudo atomic resolution of chikungunya virus and antibodies show mechanisms of neutralization. eLife 2, e00435 (2013).
pmcid: 3614025
doi: 10.7554/eLife.00435
pubmed: 23577234
Johnston, R. E. & Smith, J. F. Selection for accelerated penetration in cell culture coselects for attenuated mutants of Venezuelan equine encephalitis virus. Virology 162, 437–443 (1988).
doi: 10.1016/0042-6822(88)90484-9
pubmed: 3341117
Russell, D. L., Dalrymple, J. M. & Johnston, R. E. Sindbis virus mutations which coordinately affect glycoprotein processing, penetration, and virulence in mice. J. Virol. 63, 1619–1629 (1989).
pmcid: 248406
doi: 10.1128/jvi.63.4.1619-1629.1989
pubmed: 2926866
Pence, D. F., Davis, N. L. & Johnston, R. E. Antigenic and genetic characterization of Sindbis virus monoclonal antibody escape mutants which define a pathogenesis domain on glycoprotein E2. Virology 175, 41–49 (1990).
doi: 10.1016/0042-6822(90)90184-S
pubmed: 2309450
Pal, P. et al. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J. Virol. 88, 8213–8226 (2014).
pmcid: 4135940
doi: 10.1128/JVI.01032-14
pubmed: 24829346
EnCheng, S. et al. Analysis of murine B-cell epitopes on Eastern equine encephalitis virus glycoprotein E2. Appl. Microbiol. Biotechnol. 97, 6359–6372 (2013).
doi: 10.1007/s00253-013-4819-8
pubmed: 23512478
Agapov, E. V. et al. Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection. Arch. Virol. 139, 173–181 (1994).
doi: 10.1007/BF01309462
pubmed: 7529989
Earnest, J. T. et al. The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies. Cell Rep. 35, 108962 (2021).
pmcid: 8055377
doi: 10.1016/j.celrep.2021.108962
pubmed: 33826892
Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46–61 (2018).
doi: 10.1038/nri.2017.106
pubmed: 29063907
Tao, M. H. & Morrison, S. L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595–2601 (1989).
doi: 10.4049/jimmunol.143.8.2595
pubmed: 2507634
Després, P., Griffin, J. W. & Griffin, D. E. Effects of anti-E2 monoclonal antibody on Sindbis virus replication in AT3 cells expressing bcl-2. J. Virol. 69, 7006–7014 (1995).
pmcid: 189620
doi: 10.1128/jvi.69.11.7006-7014.1995
pubmed: 7474120
Levine, B. et al. Antibody-mediated clearance of alphavirus infection from neurons. Science 254, 856–860 (1991).
doi: 10.1126/science.1658936
pubmed: 1658936
Navaratnarajah, C. K. & Kuhn, R. J. Functional characterization of the Sindbis virus E2 glycoprotein by transposon linker-insertion mutagenesis. Virology 363, 134–147 (2007).
doi: 10.1016/j.virol.2007.01.006
pubmed: 17306321
Fox, J. M. et al. A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. PLoS Pathog. 16, e1008743 (2020).
pmcid: 7433899
doi: 10.1371/journal.ppat.1008743
pubmed: 32760128
Lee, C. Y. et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog. 7, e1002390 (2011).
pmcid: 3228792
doi: 10.1371/journal.ppat.1002390
pubmed: 22144891
Strauss, E. G., Stec, D. S., Schmaljohn, A. L. & Strauss, J. H. Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants. J. Virol. 65, 4654–4664 (1991).
pmcid: 248920
doi: 10.1128/jvi.65.9.4654-4664.1991
pubmed: 1714515
Roehrig, J. T. et al. Identification of monoclonal antibodies capable of differentiating antigenic varieties of Eastern equine encephalitis viruses. Am. J. Trop. Med. Hyg. 42, 394–398 (1990).
doi: 10.4269/ajtmh.1990.42.394
pubmed: 2158755
Mendoza, Q. P., Stanley, J. & Griffin, D. E. Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: definition of epitopes and efficiency of protection from fatal encephalitis. J. Gen. Virol. 69, 3015–3022 (1988).
doi: 10.1099/0022-1317-69-12-3015
pubmed: 2462014
Schmaljohn, A. L., Johnson, E. D., Dalrymple, J. M. & Cole, G. A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297, 70–72 (1982).
doi: 10.1038/297070a0
pubmed: 6280072
Schmaljohn, A. L., Kokubun, K. M. & Cole, G. A. Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein. Virology 130, 144–154 (1983).
doi: 10.1016/0042-6822(83)90124-1
pubmed: 6195815
Stanley, J., Cooper, S. J. & Griffin, D. E. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J. Virol. 58, 107–115 (1986).
pmcid: 252882
doi: 10.1128/jvi.58.1.107-115.1986
pubmed: 2419592
Kim, A. S. et al. Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. Cell 184, 4414–4429.e19 (2021).
pmcid: 8382027
doi: 10.1016/j.cell.2021.07.006
pubmed: 34416146
Williamson, L. E. et al. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Cell 184, 4430–4446.e22 (2021).
pmcid: 8418820
doi: 10.1016/j.cell.2021.07.033
pubmed: 34416147
Calvert, A. E. et al. Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection. Virology 565, 13–21 (2022).
doi: 10.1016/j.virol.2021.09.007
pubmed: 34626907
Fox, J. M. et al. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aav5062 (2019).
doi: 10.1126/sciimmunol.aav5062
pmcid: 6629435
pubmed: 31101672
Tuekprakhon, A. et al. Broad-spectrum monoclonal antibodies against chikungunya virus structural proteins: promising candidates for antibody-based rapid diagnostic test development. PLoS ONE 13, e0208851 (2018).
pmcid: 6296674
doi: 10.1371/journal.pone.0208851
pubmed: 30557365
Marston, H. D., Paules, C. I. & Fauci, A. S. Monoclonal antibodies for emerging infectious diseases — borrowing from history. N. Engl. J. Med. 378, 1469–1472 (2018).
doi: 10.1056/NEJMp1802256
pubmed: 29513615
Simoes, E. A. et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151, 34–42 (2007).
doi: 10.1016/j.jpeds.2007.02.032
pubmed: 17586188
Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).
pmcid: 7584396
doi: 10.1038/s41586-020-2548-6
pubmed: 32668443
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
doi: 10.1038/s41586-020-2349-y
pubmed: 32422645
Broeckel, R. et al. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl. Trop. Dis. 11, e0005637 (2017).
pmcid: 5491320
doi: 10.1371/journal.pntd.0005637
pubmed: 28628616
Burke, C. W. et al. Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure. PLoS Pathog. 15, e1008157 (2019).
pmcid: 6907853
doi: 10.1371/journal.ppat.1008157
pubmed: 31790515
Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aaw6647 (2019).
doi: 10.1126/sciimmunol.aaw6647
pmcid: 6629435
pubmed: 31101672
August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against chikungunya virus. Nat. Med. 27, 2224–2233 (2021).
pmcid: 8674127
doi: 10.1038/s41591-021-01573-6
pubmed: 34887572
Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544–1555 (2020).
doi: 10.1056/NEJMoa2024671
pubmed: 32722908
Gorchakov, R. et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J. Virol. 86, 6084–6096 (2012).
pmcid: 3372191
doi: 10.1128/JVI.06449-11
pubmed: 22457519
Edelman, R. et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62, 681–685 (2000).
doi: 10.4269/ajtmh.2000.62.681
pubmed: 11304054
Pittman, P. R. et al. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14, 337–343 (1996).
doi: 10.1016/0264-410X(95)00168-Z
pubmed: 8744562
Paessler, S. et al. Recombinant Sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J. Virol. 77, 9278–9286 (2003).
pmcid: 187387
doi: 10.1128/JVI.77.17.9278-9286.2003
pubmed: 12915543
Paessler, S. et al. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J. Virol. 80, 2784–2796 (2006).
pmcid: 1395430
doi: 10.1128/JVI.80.6.2784-2796.2006
pubmed: 16501087
Rossi, S. L. et al. IRES-containing VEEV vaccine protects cynomolgus macaques from IE Venezuelan equine encephalitis virus aerosol challenge. PLoS Negl. Trop. Dis. 9, e0003797 (2015).
pmcid: 4447396
doi: 10.1371/journal.pntd.0003797
pubmed: 26020513
Trobaugh, D. W., Sun, C., Dunn, M. D., Reed, D. S. & Klimstra, W. B. Rational design of a live-attenuated Eastern equine encephalitis virus vaccine through informed mutation of virulence determinants. PLoS Pathog. 15, e1007584 (2019).
pmcid: 6386422
doi: 10.1371/journal.ppat.1007584
pubmed: 30742691
Tucker, P. C. & Griffin, D. E. Mechanism of altered Sindbis virus neurovirulence associated with a single-amino-acid change in the E2 glycoprotein. J. Virol. 65, 1551–1557 (1991).
pmcid: 239937
doi: 10.1128/jvi.65.3.1551-1557.1991
pubmed: 1995953
Wang, E. et al. Chimeric Sindbis/Eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine 25, 7573–7581 (2007).
pmcid: 2094013
doi: 10.1016/j.vaccine.2007.07.061
pubmed: 17904699
Plante, K. et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 7, e1002142 (2011).
pmcid: 3145802
doi: 10.1371/journal.ppat.1002142
pubmed: 21829348
Roques, P. et al. Attenuated and vectored vaccines protect nonhuman primates against chikungunya virus. JCI Insight 2, e83527 (2017).
pmcid: 5358498
doi: 10.1172/jci.insight.83527
pubmed: 28352649
Robinson, D. M., Cole, F. E. Jr, McManus, A. T. & Pedersen, C. E. Jr. Inactivated Mayaro vaccine produced in human diploid cell cultures. Mil. Med. 141, 163–166 (1976).
doi: 10.1093/milmed/141.3.163
pubmed: 815839
Tiwari, M. et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus. Vaccine 27, 2513–2522 (2009).
doi: 10.1016/j.vaccine.2009.02.062
pubmed: 19368794
Akahata, W. et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334–338 (2010).
pmcid: 2834826
doi: 10.1038/nm.2105
pubmed: 20111039
Goo, L. et al. A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all chikungunya virus genotypes. J. Infect. Dis. 214, 1487–1491 (2016).
pmcid: 5091377
doi: 10.1093/infdis/jiw431
pubmed: 27655868
Ko, S. Y. et al. A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aav3113 (2019).
doi: 10.1126/scitranslmed.aav3113
pmcid: 7416666
pubmed: 31801887
Brandler, S. et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31, 3718–3725 (2013).
doi: 10.1016/j.vaccine.2013.05.086
pubmed: 23742993
Ramsauer, K. et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15, 519–527 (2015).
doi: 10.1016/S1473-3099(15)70043-5
pubmed: 25739878
Wang, D. et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29, 2803–2809 (2011).
pmcid: 3061842
doi: 10.1016/j.vaccine.2011.01.108
pubmed: 21320541
Henning, L., Endt, K., Steigerwald, R., Anderson, M. & Volkmann, A. A monovalent and trivalent MVA-based vaccine completely protects mice against lethal Venezuelan, Western, and Eastern equine encephalitis virus aerosol challenge. Front. Immunol. 11, 598847 (2020).
doi: 10.3389/fimmu.2020.598847
pubmed: 33542715
Tatsis, N. et al. Adenoviral vectors persist in vivo and maintain activated CD8
pmcid: 1976365
doi: 10.1182/blood-2007-02-062117
pubmed: 17510320
Chang, L. J. et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384, 2046–2052 (2014).
doi: 10.1016/S0140-6736(14)61185-5
pubmed: 25132507
Chen, G. L. et al. Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial. JAMA 323, 1369–1377 (2020).
pmcid: 7156994
doi: 10.1001/jama.2020.2477
pubmed: 32286643
Reisinger, E. C. et al. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 392, 2718–2727 (2019).
doi: 10.1016/S0140-6736(18)32488-7
pubmed: 30409443
Folegatti, P. M. et al. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat. Commun. 12, 4636 (2021).
pmcid: 8324904
doi: 10.1038/s41467-021-24906-y
pubmed: 34330906
Paessler, S. & Weaver, S. C. Vaccines for Venezuelan equine encephalitis. Vaccine 27, D80–D85 (2009).
doi: 10.1016/j.vaccine.2009.07.095
pubmed: 19837294
Pierson, B. C. et al. Safety and immunogenicity of an inactivated Eastern equine encephalitis virus vaccine. Vaccine 39, 2780–2790 (2021).
doi: 10.1016/j.vaccine.2021.03.030
pubmed: 33888325
Rappuoli, R. Reverse vaccinology. Curr. Opin. Microbiol. 3, 445–450 (2000).
doi: 10.1016/S1369-5274(00)00119-3
pubmed: 11050440
Santiago, C. et al. Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity 26, 299–310 (2007).
pmcid: 7111020
doi: 10.1016/j.immuni.2007.01.014
pubmed: 17363299
Sasaki, T. et al. Structural basis for Gas6-Axl signalling. EMBO J. 25, 80–87 (2006).
doi: 10.1038/sj.emboj.7600912
pubmed: 16362042
Soumahoro, M. K. et al. The chikungunya epidemic on La Réunion Island in 2005–2006: a cost-of-illness study. PLoS Negl. Trop. Dis. 5, e1197 (2011).
pmcid: 3114750
doi: 10.1371/journal.pntd.0001197
pubmed: 21695162
Feldstein, L. R. et al. Estimating the cost of illness and burden of disease associated with the 2014-2015 chikungunya outbreak in the U.S. Virgin Islands. PLoS Negl. Trop. Dis. 13, e0007563 (2019).
pmcid: 6668848
doi: 10.1371/journal.pntd.0007563
pubmed: 31323020
Semenza, J. C. & Menne, B. Climate change and infectious diseases in Europe. Lancet Infect. Dis. 9, 365–375 (2009).
doi: 10.1016/S1473-3099(09)70104-5
pubmed: 19467476
Tsetsarkin, K. A., Vanlandingham, D. L., McGee, C. E. & Higgs, S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 3, e201 (2007).
pmcid: 2134949
doi: 10.1371/journal.ppat.0030201
pubmed: 18069894
Suhrbier, A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat. Rev. Rheumatol. 15, 597–611 (2019).
doi: 10.1038/s41584-019-0276-9
pubmed: 31481759